secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001437749-24-026563
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar doses first patient in Phase 1 MNPR-101-Zr trial; favorable safety and biodistribution data
--------------------------------------------------------------------------------

- First patient dosed in open-label Phase 1 imaging trial of MNPR-101-Zr; well-tolerated with no serious adverse reactions.
- Red bone marrow radiation dose ~14 mGy, roughly 150 times below the accepted limit of 2-3 Gy.
- No unanticipated or excessive uptake in critical organs; biodistribution aligns with preclinical data.
- Initial patient has metastatic cancer not known for high uPAR expression; study to include high-uPAR cancers.
- COO Andrew Cittadine: data increases confidence to advance Phase 1 and prepare therapeutic study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924026563/0001437749-24-026563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924026563/mnpr20240812_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer